Perspectives and Update on the Global Shortage of Verteporfin (Visudyne).

Details

Ressource 1Download: 38753294.pdf (330.34 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_21D97B23BEB1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Perspectives and Update on the Global Shortage of Verteporfin (Visudyne).
Journal
Ophthalmology and therapy
Author(s)
Sirks M.J., Subhi Y., Rosenberg N., Hollak CEM, Boon CJF, Diederen RMH, Yzer S., Ossewaarde-van Norel J., de Jong-Hesse Y., Schlingemann R.O., Moss R.J., van Dijk EHC
ISSN
2193-8245 (Print)
Publication state
Published
Issued date
07/2024
Peer-reviewed
Oui
Volume
13
Number
7
Pages
1821-1831
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
An ongoing global shortage of verteporfin (Visudyne <sup>®</sup> ) limits the treatment possibilities for several chorioretinal diseases, including central serous chorioretinopathy, choroidal hemangioma, and polypoidal choroidal vasculopathy. Verteporfin is required to perform photodynamic therapy in these ocular diseases. Therefore, the current situation has a substantial impact on eye care worldwide. The worldwide supply of verteporfin appears to be manufactured by a single factory, which is situated in the United States. The distribution of verteporfin is done by different companies for different regions of the world. Official communication on the shortage by the responsible companies has been scarce and over the past years several promises with regards to resolution of the shortage have not been fulfilled. The delivery of new batches of verteporfin is at irregular intervals, unpredictable, and may not be fairly balanced between different regions or countries in the world. To ensure a fair distribution of available verteporfin within a country, several measures can be taken. In the Netherlands, a national committee, consisting of ophthalmologists, is in place to arrange this. On the European level, the European Union and European Medicine Agency have plans to monitor medicine shortages more closely and to intervene if necessary. With a more intensified monitoring and regulation of medicine supplies, future impending shortages may be prevented. Remarkably, the amount of medicine shortages is increasing, having a significant and sometimes irreversible impact on patient care. Thus, efforts should be undertaken to minimize the consequences and, whenever possible, to prevent future medicine shortages.
Keywords
Central serous chorioretinopathy, Choroidal hemangioma, Photodynamic therapy, Polypoidal choroidal vasculopathy, Verteporfin
Pubmed
Web of science
Open Access
Yes
Create date
17/05/2024 9:22
Last modification date
18/06/2024 7:11
Usage data